Status:
COMPLETED
18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Lead Sponsor:
Biyun Wang, MD
Conditions:
HER2-positive Breast Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/c...
Eligibility Criteria
Inclusion
- Pathologically confirmed HER2 positive breast cancer
- Treated with Pyrotinib in the metastatic settings
- Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine were included in this study
Exclusion
- Incomplete medical history
- Loss of follow up
Key Trial Info
Start Date :
September 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 24 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04756921
Start Date
September 1 2018
End Date
July 24 2020
Last Update
February 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032